Global Biomarkers Market – Market
Forecast & Trends
The Global Biomarkers Market was prized
at USD 40.1 billion in 2019, and it is predictable to reach USD 101.2 billion
by 2026, at a CAGR of 14.2 %, over the forecast period.
Development in the global biomarkers
industry is mainly driven by reasons such as increasing diagnostic applications
of biomarkers, increasing R&D funding for pharma and biotech companies, a
growing number of CROs, and low cost of clinical trials in emerging countries,
the high occurrence of cancer, and new initiatives for research. On the other
hand, high capital savings and low cost-benefit ratio poorly suitable
regulatory and repayment systems, and technical issues related to sample group
and storage are the major elements confining the development of this market.
Global Biomarkers Market – Overview
biomarker is a material that can be presented among creatures to inspect organ
functions or other features of their health. A biomarker is objectively
evaluated and measured as an indication of typical pathogenic processes,
biological processes, or pharmacologic responses to therapeutic interventions.
Biomarkers indicate a wide variety of illnesses or health features along with
the type or level of contact to genetic susceptibility to environmental
exposure, environmental factor, genetic responses markers of clinical or
subclinical diseases, and pointers of response to therapy.
Increasing usage of biomarkers in cancer
treatment is driving the market growth.
are used in application areas such as companion diagnostics, personalized
medicines, and other diagnostic areas, including drug discovery and growth and
disease risk assessment. These growing diagnostic uses of biomarkers are
predictable to drive market growth in the coming years. Companion diagnostics
and biomarkers have become progressively pertinent in the practice of medicine,
foremost to improved diagnosis, dealing, and monitoring across several disease
areas. It can be used to recognize patients likely to reply well to certain
drugs or cure options. These diagnostics are often used in combination with a
Technological advancements have permitted the
grouping of biomarkers with novel drugs for precise diagnosis and following
cure options. For instance, biomarkers can be functional for the cure of
several neurological diseases by stalking brain health and activity by
examining biomolecules. Nascent developments, such as biomarker signatures,
have augmented the treatment rate of nervous disorders resulting in early
diagnosis, non-invasive testing, and rapid drug development.
Biomarkers Market: Segmentation
Based on type, the
biomarkers market is segmented into safety, efficacy, and validation
biomarkers. The effectiveness biomarkers segment is additional categorized into
pharmacodynamic, predictive, surrogate and prognostic biomarkers.
In 2016, the safety
biomarkers section accounted for the main share of the biomarkers market.
However, the usefulness biomarkers segment is projected to record the highest
CAGR during the prediction period. The efficacy biomarkers segment is
predictable to register the highest growth during the forecast period, chiefly
due to the wide variety of products obtainable in the market and the growing
acceptance of these biomarkers for various applications.
By application, the
personalized medicine segment is expected to grow at the highest CAGR during
the forecast period. Biomarkers are mainly used in disease risk assessment,
diagnostics, drug discovery & development, personalized medicine, and other
applications (DNA fingerprinting, ecotoxicology, and forensics). The use of
biomarkers for the analysis of complex diseases, including neurological
disorders, cancer, cardiovascular disorders, is increasing. This primary factor
drives the growth of the investigative segment of the biomarker market. However,
with rising demand for custom-designed treatment plans for diseases like
cancer, the personalized medicine segment is expected to witness the highest
development in the forecast period.
By disease indication,
cardiovascular disorder segment is expected to grow at the highest CAGR during
the forecast period
are widely used in the analysis and management of multiple diseases.
Physiological levels of biomarkers also alteration upon the administration of
drugs. The study of numerous biomarkers helps clinicians make meaningful
choices about the diagnosis, disease stage, therapy plan, and forecast in
on the disease indication, this report is segmented into cancer, cardiovascular
disorders, neurological illnesses, immunological disorders, and other illness
indications. Cancer forms the most significant segment primarily due to the
growing occurrence of disease internationally and the increasing use of
biomarkers in cancer diagnostics.
the Global Biomarkers Market is divided into North America, Europe,
Asia-Pacific, and LAMEA regions.
Global Biomarkers Market: Regional
America conquered the biomarkers market globally in 2018 and is likely to
remain leading over the forecast period as well. This local dominance can be
attributed to the regional occurrence of major pharmaceutical and biotechnology
companies, increasing adoption of the newest technologies, and recognized
healthcare infrastructure. The U.S. is the leading biomarker market in North
America, which is expected to list the highest CAGR in the years ahead.
The Asia Pacific
region is predictable to record high development in the biomarkers market
internationally in the years ahead. The rising frequencies of chronic diseases
like cancer, neurological disorders, and cardiovascular diseases, rising
support of the local governments for drug discovery and growth programs,
quickening biomarkers mindfulness for disease analysis, and large patient pool
are the major elements boosting the biomarkers market development in the Asia
Pacific. China, Japan, and India are forecast to be major funders to the Asia
Pacific biomarkers market in the future. The promising environment for clinical
trials in the Asia Pacific is likely to fuel the biomarkers market over the
N.V., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer
Inc., Merck KGaA, Bio-Rad Laboratories, Abbott Laboratories, EKF Diagnostics,
Enzo Biochem Inc., Meso Scale Diagnostics, LLC, Signosis, and PerkinElmer Inc.
and other prominent players.
March 2020, F. Hoffmann-La Roche Ltd announced the approval by the US Food and
Drug Administration (FDA) for its CINtec PLUS Cytology as the first
biomarker-based triage test for women whose primary cervical cancer screening
results are positive for the human papillomavirus (HPV) using the cobas 4800
February 2018, Evidation Health announced the launch of their new project
DisCover which is a 10,000-person chronic pain study. The key aim is to use
activity trackers, health apps, and other more traditional data point and
develop a digital biomarkers for chronic pains.
By Disease Indication
ØDrug Discovery and
East & Africa
The objective of the Study:
analyze and forecast the Global Biomarkers Market size of the market in terms
examine the careful market segmentation and forecast the market size, in terms
of value, based on the region by segmenting.
Ø The Global
Biomarkers Market segmented into five regions, namely, North America, Europe,
Asia Pacific, Middle East, South America, and their leading countries.
outline, categorized, and forecast the Global Biomarkers Market based on the Product,
Type, By Disease Indication, By Application and Regional.
examine competitive developments like by Product, Type, By Disease Indication,
By Application and Regional within the Global Biomarkers Market.
highlight the impact analysis of the factors affecting the market dynamics such
as growth drivers.
strategically profile the key players and comprehensively analyze their market
shares along with detailing the competitive landscape for market leaders.
Business Questions Answer by the Report
Ø How will the
market drivers, restraints, and opportunities affect the market dynamics?
Ø What will be the
market size in terms of value and volume and market statistics with a detailed
Ø Which segment
dominates the market or region, and one will be the fastest - growing, and why?
Ø A comprehensive
survey of the competitive landscape and the market participant players
Ø Analysis of
strategy adopted by the key player and their impact on other players.
Customization Scope for the Client
satisfaction is our first and last priority, and that is why BlueWeave Consulting
offers customization according to Company’s specific needs. The following
customization options are available for the report:
Additional Company Information
Ø With five
additional company detail analysis
Ø Detailed segment